Skip to main content

Table 1 Review of SABR literature for primary RCC

From: TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II

Author / Year Patients Follow-up (months - Median or Mean) Average marginal dose (Gy) Outcome - Crude Local control Estimated 2 year LC Overall Survival Median Toxicities
Chang et al. [7] 2016 16 19 30-40Gy in 5 fractions 100% NR NR 1 grade 2 acute toxicity and 2 grade 4 late toxicities
Gilson et al. [8] 2006 33 17 Median 40Gy in 5 fractions 94% 92 NR NR
Lo et al. [9] 2014 3 21.7 40Gy in 5 fractions 100% NR NR Early: 1 x Grade 1 nausea
Late: nil
McBride et al. [10] 2013 (abstract) [prospective] 15 36.7 Median 33Gy in 3 fractions 87%
1 failure at 30.7 mo
1 failure at 31.2 mo
NR NR 1 x Grade 3 renal toxicity
5 x Grade 1 fatigue
2 x Grade 1 nausea
Nair et al. [27] 2013 3 13.3 39Gy in 3 fractions 100% NR NR Early: 1 x Grade 1 nausea
Late: Nil
Nomiya et al. [28] 2008 10 57.5 Median 4.5Gy x 16fx 100% 100 5 year OS 74% 10% Grade 4 toxicity, no other toxicities > Grade 1
Qian et al. [29] 2003 (abstract) 20 12 40Gy in 5 fractions 93% 86 NR NR
Pham et al. [15] 2014 [prospective] 20 6 26Gy in 1 fraction 42Gy in 3 fractions NR NR NR 60% Grade 1–2
No Grade 3, Grade 4
Ponksy et al. [30] 2015 [prospective] 19 13.7 Max 48Gy in 4 fractions NR NR NR 5.2% Grade 2, 15.8% Grade 3–4
Siva et al. [16] [prospective] 33 24 26Gy in 1 fraction 42Gy in 3 fractions 97% 100% 2 year OS 92% 78% Grade 1–2
3% Grade 3
Svedman et al. [31] 2006 [prospective] 5 52 40Gy in 4 or 5 fractions, 45Gy in 3 fractions 80% 91 Median survival 32 months 89% Grade 1–2, 4% Grade 3
Svedman et al. [32] 2008 7 39 40Gy in 4 fractions 86% 91 NR 58% Grade 1–2, nil else
Teh et al. [33] 2007 (abstract) 2 9 24Gy–48Gy in 3–6 fx 100% 100 NR NR
Staehler et al. [18] 2015 b [prospective] 30a 28.1 25Gy in 1 fraction 98%
(at 9mo) b
NR Not attained after median 28.1 months+ 13% Grade 1–2
nil else
Wang et al. [13] 2014 9 38.3 36-51Gy to 50% isodose line at 3-5Gy per fraction 5 year LC 43% NR 5 year OS 35% Early: 44% Grade 1 (GI, haem.)
Late: 22% Grade 2 (GI)
Wersall et al. [34] 2005 8 37 40Gy in 4 or 5 fractions, 45Gy in 3 fractions 100% 100 Median survival 58+ months 20% Grade 1–2, 19% Grade 3, nil Grade 4+
  1. a report included an additional 15 patients with Transitional cell carcinoma;
  2. b pooled results with patients treated for TCC
  3. NR not reported, Gy Gray